intergroupe de la société française de lutte contre les cancers et les leucémies de l'enfant et de l'adolescent

la sfce est une société savante, issue de la fusion en 2003 de la société française d’oncologie pédiatrique (sfop), du children leukemia group de l’eortc, du fralle, et du gfecle, coordonnant au niveau national la prise en charge et la recherche sur les cancers des patients âgés de 0 à 19 ans. la reconnaissance de la sfce en tant qu’intergroupe coopérateur par l’inca, lui permettra de collaborer de plein droit en partenariat a) avec les autres intergroupes français : lysa-lysarc, intersarc et à venir (leucémies et tumeurs cérébrales) dans le cadre de projets nationaux portant sur des pathologies s’étendant sur toutes les classes d’âge. la mise en place d’études communes pour ces populations est un enjeu majeur. b) avec les autres sociétés pédiatriques nationales au sein de la branche européenne de la société internationale d’oncologie pédiatrique (siop-e) où son implication doit lui permettre d’être « leader » c) avec le groupe go-aja.

sfce is the french national pediatric hemato-oncology scientific society. it was created in 2003 by the fusion of the « société française d’oncologie pédiatrique » (sfop), the children leukemia group of eortc, the fralle (leukemia group), and the « groupe français d’etude des cancers et leucémies de l’enfant ». it is coordinating care and research at the national level for all cancers between birth and the age of 19. labelization of sfce intergroup by inca will help develop collaboration a) with others french existing intergroups like lysa-lysarc, intersarc, and the forthcoming one focusing on leukemia and cns tumors. these collaborations will focus on diseases occurring in children as well as young adult patients. b) with other national pediatric hemato-oncology societies within siop-europe. sfce may achieve leader position at the european level. c) with the adolescent and young adult french oncology group. pediatric oncology is an aggregate of orphan diseases which management needs strong interaction between clinical care and research. the primary mission of the “société française de lutte contre les cancers et leucémies de l’enfant” (sfce) is to improve cure rates of children and adolescent with cancer, while reducing acute and late effects related to treatment. the necessity for a unique group taking care of the organization of care for children and aya with cancer in the whole country, in collaboration with translational, basic, epidemiological and social research is the hallmark of our society. given the rarity of these diseases, pediatric oncology research is developing at the european and even transatlantic level and funding problems are crucial and not solved. our group is covering all the major segments of pediatric oncology: malignant hematology, cns tumors, sarcomas, embryonal tumors and all other tumors occurring in children and adolescents. in order to face the challenges, pediatric hemato-oncology is organized in france since 2003 through a unique scientific society. twenty committees of the sfce are gathering specialists including pediatricians, hematologists, surgeons, bio pathologists, radiotherapists and radiologists from 30 centers. these committees are preparing future protocols and conducting trials or non-interventional studies in collaboration with other national groups inside siop-europe or other international inter-groups. special interactions exist with the innovative therapy for children with cancer (itcc) group. at the national level, interactions exist with intersarc through members of the recently created go-aja group (“groupe onco-hématologie adolescents et jeunes adultes”) for primary bone tumor trials, with the sfgm-tc (“société française de greffe de moelle et de thérapie cellulaire”) for pediatric projects conducted by the sfce committee for stem cell transplantation and anocef for brain tumors. other interactions are planned with the lysa group, and with the future adult leukemia and cns tumors intergroups. the project integrating care and research named « hope-epi » in collaboration with the “institut national de la santé et de la recherche médicale” (inserm) is interconnecting registries, clinical data from sfce centers, a tumor specimen and constitutional dna virtual bank (biocap), and large cohorts of cured patients with long term follow-up (fccss and lea). it should allow constituting a national cohort by the mutual efforts in data collection and validation of health events related to cancer in children. following the recommendation of the third national cancer plan, large ngs studies of pediatric tumor specimen will help elaborate new targeted therapeutic approaches, which will not be only disease oriented. the recognition of sfce as an intergroup shall open new opportunities for the development of research in pediatric hemato-oncology.